Pembrolizumab and chemo for early-stage triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have been diagnosed with early-stage triple-negative breast cancer (TNBC) that was completely removed by surgery.
- Your tumor's immune cell level (TILs) is between 30% and 75% (depending on your age).
- You have not had prior chemotherapy or certain targeted therapies in the last year.
- You are not pregnant or breastfeeding, and agree to use birth control during the study.
- You are generally healthy enough for daily activities (ECOG 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests if continuing pembrolizumab after surgery can help prevent breast cancer from coming back in people with triple-negative breast cancer who still had some cancer after initial chemo and pembrolizumab before surgery.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This Phase 1 study tests pembrolizumab (an immune medicine) to see how it affects the tumor and its surroundings in triple-negative breast cancer. It’s mainly looking at safety and early signs of benefit, especially in a limited, early-stage breast tumor.
This trial tests two different sequences of chemotherapy combined with the immunotherapy drug pembrolizumab (Keytruda) before surgery for high-risk triple-negative breast cancer. It aims to see which order works better to shrink tumors and improve outcomes.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.